"Some of the discussion going on right now is how to improve the morbidity of bladder cancer treatment by pursuing such things…as bladder sparing approaches when feasible…and so, I think that’s very exciting,” says Mohummad M. Siddiqui, MD.
In this video, Mohummad M. Siddiqui, MD, discusses recent developments in the bladder cancer space and shares highlights from the bladder cancer course presented at the 2021 Society of Urologic Oncology Annual Meeting. Siddiqui is an associate professor of surgery and director of urologic oncology and robotic surgery at the University of Maryland, Baltimore.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.